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HyperCKemiaSeveral studies have reported rhabdomyolysis induced by various drugs but not by the antiepileptic drug
levetiracetam. We present a case of suspected levetiracetam-induced rhabdomyolysis. A 29-year-old woman
was hospitalized for generalized tonic–clonic seizure and given levetiracetam for the ﬁrst time. One day after
starting levetiracetam, she developed myalgia, particularly backache, and weakness in both lower limbs. Based
on her clinical symptoms and blood test results indicating hyperCKemia, our diagnosis was levetiracetam-
induced rhabdomyolysis. Withdrawal of levetiracetam immediately improved the clinical symptoms and
hyperCKemia. Thisﬁrst report of suspected levetiracetam-induced rhabdomyolysis provides important information
for treating patients early in levetiracetam administration.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Levetiracetam is a relatively new antiepileptic drug that achieves its
antiepileptic action by binding to synaptic vesicle protein 2A (SV2A) [1].
It was approved for clinical use in the United States in 1999 and in
Japan in 2010 as a combination therapy with other antiepileptic drugs
for partial-onset seizures (including secondary generalized seizures), for
which other antiepileptic drugs are ineffective. The rate of adverse effects
observed in patients taking levetiracetam in a clinical trial in Japan was
90.2% in adults and58.9% in infants [2]. Themajor adverse effects reported
were nasopharyngitis (53.0%), somnolence (35.5%), headache (19.9%),
dizziness (17.5%), diarrhea (13.8%), and constipation (10.9%), while
other serious adverse effects included Stevens–Johnson syndrome, Lyell
syndrome, serious blood dysfunction, liver failure, hepatitis, pancreatitis,
aggressiveness, and suicide attempt [2]. However, no cases of rhabdomy-
olysis have been reported with its use. Here, we report a case of rhabdo-
myolysis in a 29-year-old woman administered levetiracetam for the
ﬁrst time, and we provide a brief review of the literature.1.1. Case report
A 29-year-old woman was admitted to our hospital in late Septem-
ber 2013 for generalized tonic–clonic seizure after a prolonged non-
convulsive seizure. She had been medicated at our hospital fort. Marianna University School of
a 216-8511, Japan. Tel.:+81 44
ama).
. This is an open access article underidiopathic epilepsy that started at 14 years of age. She had no clinical
symptoms such as rhabdomyolysis or hyperCKemia when intravenous
phenytoin was administered for her last seizure, which occurred in
mid-January 2010. Epilepsy was being well controlled by oral sodium
valproate (VPA) 1000 mg daily and clobazam 20 mg daily since her
last attack. During this treatment, a blood test revealed a normal
serum creatine kinase (CK) level (69 IU/L) and an optimal blood VPA
concentration (82.2 μg/mL). As she recently expressed a desire to con-
ceive, we reduced the VPA dose from 1000 mg to 800 mg daily in
mid-April 2012 because no spikes had been observed on electroenceph-
alography (EEG) and no clinical seizures had occurred in the past
2 years. We further reduced the VPA dose to 600 mg daily in late De-
cember 2012 and to 400 mg daily in mid-March 2013 because she
had not experienced any seizures with tapering the VPA dose (Fig. 1).
In late September 2013, she developed transient disturbance of
consciousness without convulsion for around 5 min while at work. An
ambulance was called for, but as her consciousness had returned by
the time the ambulance arrived, she walked to the outpatient clinic at
our hospital. However, around 4 h later, she developed a generalized
tonic–clonic seizure during an EEG in the outpatient examination
room and was consequently hospitalized. Electroencephalography re-
vealed paroxysmal diffuse polyspike–waves following diffuse rhythmic
waves in the tonic phase and a diffuse spike and slow-wave complex in
the clonic phase (Figs. 2A–D). She was a nonsmoker, did not drink, and
had no past history of allergic diseases. Idiopathic epilepsy was the only
remarkable factor in her past history.
On ﬁrst presentation, blood pressure was 102/51 mm Hg, and pulse
was regular at 117 beats/min. Respiratory rate was 12 times/min, and
SpO2 was 100% in an air-conditioned room. General physical ﬁndingsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Sodium valproate dose was gradually reduced to 400 mg daily in mid-March 2013 because she had not experienced any seizures during tapering.
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normal limits, including a normal serum CK level (149 IU/L), and
chest X-ray and ECG ﬁndings were also normal. Plain computed tomog-
raphy of the head revealed no intracranial abnormalities or sinusitis.
The patient was admitted to our department because of the general-
ized tonic–clonic seizure, which developed during the EEG, and after
this episode, she was started on intravenous phenytoin 250 mg daily.
She had not experienced any seizures since starting intravenous phe-
nytoin. A single dose of phenytoin 250 mg was given on hospital day
2, and intravenous medication was discontinued the same day (total
phenytoin dose, 500 mg over 2 days). Levetiracetam 1000 mg daily
and VPA 800 mg daily were started from hospital day 3. She developed
myalgia, particularly backache, and weakness in both lower limbs after
starting levetiracetam and VPA on hospital day 4. However, she was
discharged because of improved clinical symptoms and because she
wished to return to work. Initial seizure control was complete, and
drug adherence was good after discharge. However, myalgia and weak-
ness were gradually aggravated, and she revisited our hospital 3 days
later. A blood test revealed hyperCKemia of 2410 IU/L and a low blood
VPA concentration of 33.6 μg/mL, and levetiracetam was immediately
withdrawn. Sodium valproate 800mg dailywas continued.Withdrawal
of levetiracetam immediately improved themyalgia and weakness, and
hyperCKemia improved rapidly to a normal level; CK was 59 IU/L
28 days after discharge. We did not measure serum myoglobin levels
but diagnosed the patient as having rhabdomyolysis induced by leveti-
racetam based on the clinical course (Fig. 1).
2. Discussion
Levetiracetam is an antiepileptic drug marketed since 2000. The
mechanism of action by binding to SV2A of levetiracetam is different
from that of other antiepileptic agents. Here, we report the ﬁrst case
of rhabdomyolysis in a patient treated with this new antiepileptic
drug, which, despite its short history of use in Japan, is now widely
prescribed due to its efﬁcacy. The present case reveals the importance
of being aware that rhabdomyolysis may develop, albeit rarely, while
on levetiracetam.
Rhabdomyolysis is often caused by traumatic events such as
accident and injury or by nontraumatic events such as dehydrationand administration of medication. Its mechanism is known to involve
fusion and necrosis of skeletal muscle cells, which causes myalgia and
weakness [3,4]. Although rhabdomyolysis can develop in response to
various agents, it is often caused by statins, ﬁbrates, antibiotics, neuro-
leptics, and traditional Chinese medicine, and its incidence is low in
users of antiepileptics. Among the limited number of antiepileptic
agents, a few cases of rhabdomyolysis with VPA, zonisamide, and phe-
nytoin have been reported [5–7]. However, no studies have reported
this adverse effect with levetiracetam. Furthermore, the medical and
pharmacological product survey forms for the medication at the time
of its approval showed that the rate of adverse effects in adults in the
clinical trial in Japan was 90.2%, while that for children was 58.9%, but
there were no cases of rhabdomyolysis reported [2]. Similarly, large-
scale clinical trials on levetiracetam, including the KEEPER™1 trial, the
SKATE™ study, and the Asia SKATE II study [8–10], reported somno-
lence (12.8–30.3%), asthenia (8.3%), dizziness (7.2–14.7%), headache
(5.9–10.3%), and fatigue (6.0–13.7%) as major adverse effects but no
cases of rhabdomyolysis (Table 1). However, although rhabdomyolysis
is not speciﬁcally indicated, the adverse effects described on themedical
interview form for levetiracetam possibly denote rhabdomyolysis
because the occurrence of backache is 3% and that of myalgia and pain
in the extremities, neck, or shoulder is b1–3% [2]. To the best of our
knowledge, few studies have reported hyperCKemia [11,12]. However,
all of these reported caseswere asymptomatic without rhabdomyolysis.
As such, the present study is the ﬁrst reported suspected case of leveti-
racetam-induced rhabdomyolysis, clinicians should consider this possi-
bility under the appropriate clinical circumstances.
Regarding the diagnosis of rhabdomyolysis, the incidence of this
condition in clinical practice is low, andmanymedications are frequent-
ly being administered at the time of its onset. Consequently, it is often
impossible to determine which medication caused the muscle damage.
The etiology of rhabdomyolysis in our case was also thought to have
been caused by 1) generalized tonic–clonic seizure or 2) intravenous
phenytoin or oral VPA and levetiracetam administration.
It is difﬁcult to determine the causative agent among the antiepilep-
tic drugs of phenytoin, VPA, and levetiracetam in the present case. Given
that rhabdomyolysis is a natural result of generalized tonic–clonic
seizure, it is usual for myalgia or weakness to appear immediately
after an epileptic episode. However, our patient was unaware of any
A B
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Fig. 2. Electroencephalography on admission showedparoxysmal diffuse polyspike–waves followingdiffuse rhythmicwaves in the tonic phase and a diffuse spike and slow-wave complex
in the clonic phase (A: tonic phase; B and C: clonic phase; D: after generalized tonic–clonic seizure).
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presented with hyperCKemia at any previous hospital visits while tak-
ing phenytoin or VPA. Furthermore, the total dose of intravenous phe-
nytoin at this time was only 500 mg, which was administered in 2
doses over 2 days (250 mg on day 1 and 250 mg on day 2), and the
bloodVPA concentrationwhenhyperCKemia appearedwas too low. Re-
garding the drug interaction between levetiracetam and phenytoin or
VPA, it has been reported that levetiracetam does not inﬂuence the
serum concentration or pharmacokinetics of phenytoin or VPA [13].
Therefore, the possibility of rhabdomyolysis being induced by phenytoin
or VPA is low. Our patient started to experiencemyalgia andweakness in
both lower limbs, as well as hyperCKemia, immediately after being
started on levetiracetam. According to medical interview forms, the
serum concentration (i.e., Cmax) of levetiracetam peaks 2–3 h after ad-
ministration and reaches a steady state 3 days after administration
when a repeat dose of levetiracetam should be given [13]. These pharma-
cokinetics coincide with the onset of clinical symptoms or hyperCKemia.
Since her signs and symptoms improved quickly once levetiracetamwas
withdrawn, the adverse effects were likely due to this drug alone. In ad-
dition, other muscle diseases known to cause rhabdomyolysis, such as
metabolic disorders (e.g., glycogen storage disease), lipid metabolism
disorders, metabolic myopathy, dystrophinopathy, certain atypical
types of mitochondrial disorders, and hypothyroidism, were clearlyruled out based on the patient's clinical course. The most likely cause of
the rhabdomyolysiswas levetiracetam, as evidenced by the close tempo-
ral relationship between exposure to the drug and onset of symptoms
and the immediate resolution of symptoms and hyperCKemia after leve-
tiracetam withdrawal.
In terms of the incidence of rhabdomyolysis due to levetiracetam, it is
difﬁcult to determine the exact number of patients taking this drug. In ad-
dition, it is conceivable that not all cases of rhabdomyolysis have been re-
ported, so it is difﬁcult to calculate its incidence. However, based on the
157 patients at our hospital taking levetiracetam, the frequency of rhab-
domyolysis was estimated to be at around 0.64%. According tomarketing
information on levetiracetam, the number of the patients taking the drug
in Japan is around 80,000 to 100,000, and the incidence of rhabdomyoly-
sis among them is reported to be 0.001 to 0.00125%, which is extremely
low.
Finally, the timing of the onset of rhabdomyolysis is reported to vary
depending on the types of medication involved. For example, with anti-
biotics, particularly quinolone, rhabdomyolysis often occurs within 1 to
6 days after commencing treatment [14], while with statins, it occurs
within a few weeks to months. In the present case, the symptoms ap-
peared within 24 h after starting levetiracetam treatment. Therefore, it
is possible that levetiracetam, much like antibiotics, can cause rhabdo-
myolysis early in treatment.
Table 1
Review of the large-scale clinical trials.
Publication year 2003 2007 2010
Study name The KEEPER™1
trial
The SKATE™
study
The Asia SKATE II
study
Total number of patients 1030 1541 251
Adverse effect
Overall (%) 38.3 50.5 73.3
Serious adverse
event (%)
0.29 1 4.4
Symptoms (%)
Somnolence 132 (12.8) 290 (18.8) 76 (30.3)
Asthenia 86 (8.3) – –
Dizziness 74 (7.2) 123 (8.0) 37 (14.7)
Headache 61 (5.9) 159 (10.3) 16 (6.4)
Fatigue – 211 (13.7) 15 (6.0)
Nausea – 58 (3.8) 14 (5.6)
Convulsion – 48 (3.1) –
Sedation – – 15 (6.0)
Lethargy – – 11 (4.4)
Vomiting – – 9 (3.6)
Abnormal coordination – – 6 (2.4)
Blurred vision – – 6 (2.4)
Insomnia – – 6 (2.4)
Rash – – 6 (2.4)
Anger – – 5 (2.0)
Upper respiratory tract
infection
– – 5 (2.0)
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We encountered the ﬁrst case of rhabdomyolysis in which levetirac-
etam was suspected as the cause. As rhabdomyolysis has the potential
to develop during the early phase of levetiracetam treatment, clinicians
should pay attention to the possible development of rhabdomyolysis
despite its rare incidence.
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